On October 4 th and 5th, PharmaMar will meet with European investors to increase awareness of the Company and to explain in detail present and future projects. This 17th annual event will host 400 ...
- The objective of the trial is to evaluate the efficacy and safety of plitidepsin in patients with COVID-19 requiring hospital admission - Plitidepsin recently obtained positive results from in vitro ...
Workers walk outside the Spanish pharmaceutical company PharmaMar amid the coronavirus disease (COVID-19) outbreak, in Colmenar Viejo MADRID (Reuters) -Shares in PharmaMar jumped almost 20% on Tuesday ...
Add Yahoo as a preferred source to see more of our stories on Google. MADRID (Reuters) - Spanish pharmaceutical company PharmaMar said on Friday a clinical trial of its cancer drug Aplidin to treat ...
This news release is available in Spanish. Madrid, July 23, 2015 - PharmaMar has entered into an exclusive license and commercialization agreement with the pharmaceutical company TTY Biopharm to ...
Sign up for our Metro US email newsletter to get news, updates, and local insights delivered straight to your inbox! (Reuters) -Spanish pharmaceutical group PharmaMar ...
PharmaMar has filed (PDF) for FDA approval of lurbinectedin in relapsed small cell lung cancer. The filing tees PharmaMar up to become the first company to win approval for a new chemical entity in ...
PharmaMar has partnered with Globant to accelerate cancer drug discovery through a new multi-agent artificial intelligence framework. Developed using Globant Enterprise AI, the system delivers over 90 ...
The FDA has accepted PharmaMar and Jazz Pharmaceuticals’ small cell lung cancer (SCLC) drug for priority review. Getting lurbinectedin on the fast track tees the partners up to learn whether the FDA ...
- PharmaMar is also eligible to receive up to $800 million in potential milestone payments in addition to royalties on net sales MADRID and DUBLIN, Jan. 22, 2020 /PRNewswire/ -- PharmaMar (MSE:PHM) ...
PharmaMar is one of the few biopharmaceutical companies to have a product on the market, another awaiting commercialisation and various more at different stages of clinical development In association ...
The new alliance has launched a multi-agent AI framework to support faster, data-driven decisions in cancer research. Agentic AI system achieves 15x faster insights with over 90% accuracy. Through ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results